Galmed Pharmaceuticals's total assets for Q2 2025 were $22.94M, an increase of 22.80% from the previous quarter. GLMD total liabilities were $2.42M for the fiscal quarter, a 33.98% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.